美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.82

+0.34801.01%

盤後：34.820.00000.00%16:15 EDT

成交量：1.41萬

成交額：48.85萬

市值：9,679.96萬

市盈率：- -

高：34.92

開：34.52

低：34.42

收：34.47

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.80

換手率：0.51%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

阿斯利康慢阻肺藥物兩項晚期臨床試驗取得成功

环球市场播报

安進股價下跌7%，創下自2025年6月以來最大單日跌幅。

DELPHI‑305 三期臨床試驗達到主要終點。

Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中，在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善

兩項驗證性試驗迎突破性結果！阿斯利康Tozorakimab再傳好消息

更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標

安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療

Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善

BMO下調安進及BioNTech評級至「與大市同步」

苑東生物：公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會

禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准

美股盤前｜英特爾、甲骨文升逾4%；諾華重挫12%，IONIS下跌10%；阿斯麥新一代EUV光刻機獲台積電和三星使用承諾

老虎资讯综合

AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間

独角兽智库

PHARVARIS的3期臨床試驗達到全部主要及次要終點。

石藥集團：SYH2083滴眼液獲臨床試驗批准

膽固醇藥物臨床試驗受挫，數十億美元研發競賽蒙上陰影

环球市场播报

諾華試驗受挫且BMO下調評級，安進股價下跌

復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准

盤前異動：安進、耐克、Bloom Energy 等個股受關注

美股異動｜安進盤前跌5.4%，諾華同靶點藥物III期臨床失敗，Lp(a)賽道遭重創

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/IBBQ/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.82,"timestamp":1789416000000,"preClose":34.472,"halted":0,"volume":14068,"hourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"16:15 EDT","volume":10,"amount":348.2,"timestamp":1789416900316,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01009514968670222,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"盤後交易","change":0.348,"latestTime":"09-14 16:46:11 EDT","open":34.52,"high":34.92,"low":34.42,"amount":488499,"amplitude":0.014505,"askPrice":35.14,"askSize":8500,"bidPrice":34.39,"bidSize":8700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":34.472,"sharesOutstanding":2520001,"nav":34.42313,"aum":95742920.24,"dividendRate":0.007412,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"16:15 EDT","volume":10,"amount":348.2,"timestamp":1789416900316,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.800018,"impliedVol":0.1149,"impliedVolPercentile":0.4861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.800018,"shares":2780001,"dividePrice":0.2581,"high":34.92,"amplitude":0.014505,"preClose":34.472,"low":34.42,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.82,"committee":0.011628,"eps":0,"divideRate":0.007412,"volume":14068,"delay":0,"ttmEps":0,"open":34.52,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":36.05,"twentyDayClose":33.8122,"sixtyDayClose":29.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665754133","title":"阿斯利康慢阻肺藥物兩項晚期臨床試驗取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2665754133","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665754133?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:45","pubTimestamp":1788875100,"startTime":"0","endTime":"0","summary":"阿斯利康周二公布慢阻肺在研药物两项成功的晚期临床试验完整结果，市场对该药创造数十亿美元营收的预期进一步升温。据阿斯利康数据，美国确诊及未确诊慢阻肺患者合计约 1600 万2600 万人，慢阻肺位列美国第五大死亡原因。阿斯利康近期将该药物销售峰值预期上调至50 亿美元以上，助力公司冲刺 2030 年整体 800 亿美元营收目标。两项临床试验同时纳入现吸烟者、既往吸烟者，覆盖全部嗜酸粒细胞水平、全部肺功能严重程度分级的患者。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inircrns9296776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BMED","MDTX","IBBJ","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375527","title":"安進股價下跌7%，創下自2025年6月以來最大單日跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375527?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:30","pubTimestamp":1788874246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIB","LU0058720904.USD","IE0009355771.USD","BK4533","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2242652126.USD","SG9999001440.SGD","BK4599","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU1061106388.HKD","AMGN","BK4139","LU2242646821.SGD","BK4585","LU2112291526.USD","TBXU","IE00B2B36J28.USD","LU0122379950.USD","BK4566","IE00B4R5TH58.HKD","LU1571399168.USD","LU2468319806.SGD","PBE","LU0320765992.SGD","IBBQ","BK4588","LU0289739699.SGD","LU0868494617.USD","PJP","LU1023059063.AUD","BK4581","LU1983299246.USD","IBB","BK4534","IE00BJT1NW94.SGD","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373053","title":"DELPHI‑305 三期臨床試驗達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373053?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:19","pubTimestamp":1788873564,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","PSYK","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665968376","title":"Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中，在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2665968376","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665968376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:18","pubTimestamp":1788873480,"startTime":"0","endTime":"0","summary":"OBERON和TITANIA两项Ⅲ期试验的结果令人鼓舞，证实tozorakimab在广泛患者人群中均能降低急性加重风险，有望帮助患者摆脱反复急性加重的困扰，获得全新的治疗选择。Tozorakimab 是首个在广泛慢阻肺病患者人群中显示出减少气道黏液栓堵塞作用的生物制剂3。Tozorakimab总体耐受性和安全性良好，唯一报告的药物不良反应为注射部位反应1,2。目前，tozorakimab已在欧盟、中国等主要市场进入上市许可审评阶段，用于治疗慢性阻塞性肺疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2237443382.USD","IBBQ","LU2237443895.HKD","LU2456880835.USD","BK4588","BK4568","LU2089984988.USD","LU2462157665.USD","LU0058720904.USD","AZN","BMED","LU2237443465.HKD","LU0708994859.HKD","IBBJ","BK4007","LU2468319806.SGD","LU0289739699.SGD","MDTX","LU0128525929.USD","LU0889565916.HKD","LU2236285917.USD","IE00B3T34201.USD","LU2237443549.SGD","LU0432979614.USD","LU1829250122.USD","AZNH","BK4585","LU2237443622.USD","LU0109394709.USD","LU0320765992.SGD","PSYK","LU1267930573.SGD","LU0310800379.SGD","LU2417539215.USD","LU0029864427.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665137530","title":"兩項驗證性試驗迎突破性結果！阿斯利康Tozorakimab再傳好消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2665137530","media":"上观新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665137530?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873273,"startTime":"0","endTime":"0","summary":"慢性阻塞性肺疾病候选药物Tozorakimab再度传来好消息：其在最新两项验证性试验中都展示出了突破性结果，有望为全球数百万接受标准吸入治疗后仍面临急性加重风险的患者带来新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868309733.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868309733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BEX","IBBQ","BEZ","BEC","BEG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732793","title":"更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732793","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873260,"startTime":"0","endTime":"0","summary":"阿斯利康抗癌药物组合在晚期临床试验中达到主要生存目标路透9月8日-阿斯利康（AstraZeneca）AZN.L周二表示，其抗癌药物Imfinzi与安进（Amgen）的AMGN.O靶向免疫疗法Imdelltra联合使用，在一项晚期临床试验中，显著提高了广泛期小细胞肺癌一线治疗患者的总生存期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S450114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880407132.USD","LU1084165304.USD","LU1487256676.USD","LU0827474353.SGD","LU0997586515.USD","LU0969580561.USD","LU0882574055.USD","IBBQ","LU0784383803.USD","IBB","LU0058720904.USD","LU0957799991.USD","LU1863844749.USD","LU2433249047.HKD","LU1023059063.AUD","BBH","BIB","PBE","PJP","LU0109394709.USD","LU0661504455.SGD","AMGN","LU1003076772.USD","LU1923622614.USD","LU1046234339.USD","LU0077335932.USD","LU1061106388.HKD","LU0289739699.SGD","LU2355687059.USD","03165","LU1829250122.USD","LU2242652126.USD","LU0203347892.USD","BK4139","LU2279689827.SGD","BK4599","LU0122379950.USD","LU0545039389.USD","LU0868494617.USD","TBXU","LU2091194634.USD","LU0920783379.SGD","IE0034235188.USD","LU0526926950.USD","LU1481599808.USD","LU0889566641.SGD","LU1170363599.USD","LU2237443465.HKD","AZN.UK","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115495471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比，该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现，无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露，但安进方面表示，其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进，安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1057294990.SGD","BK4585","BK4581","LU0868494617.USD","BK4599","LU1983299246.USD","LU0058720904.USD","IBB","IE00B4R5TH58.HKD","LU1571399168.USD","SG9999001440.SGD","LU2089984988.USD","PJP","IBBQ","LU0289739699.SGD","BK4588","BBH","BK4534","LU1023059063.AUD","IE0009355771.USD","LU0889565916.HKD","LU2242652126.USD","IE00BJJMRZ35.SGD","BIB","PBE","AMGN","IE00BJT1NW94.SGD","LU0320765992.SGD","LU1061106388.HKD","IE00B2B36J28.USD","LU2242646821.SGD","LU0109394709.USD","IE0002141913.USD","TBXU","LU2112291526.USD","BK4533","IE00BFTCPJ56.SGD","BK4139","BK4566","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109517247?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法，于一线广泛期小细胞肺癌治疗领域，取得了具有划时代意义的总生存期提升。这一突破性进展，不仅为患者带来了新的曙光，也重塑了该领域的治疗格局。从数据层面观察，联合治疗方案的生存获益尤为显著，堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0868494617.USD","BK4599","IE0002141913.USD","LU2242646821.SGD","IE0009355771.USD","LU0320765992.SGD","LU1983299246.USD","BIB","LU0058720904.USD","IBB","LU1571399168.USD","LU2242652126.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","IE00BJJMRZ35.SGD","BK4534","LU2468319806.SGD","BK4581","IBBQ","SG9999001440.SGD","TBXU","LU2089984988.USD","BK4566","LU1023059063.AUD","LU1057294990.SGD","BBH","IE00B2B36J28.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU2112291526.USD","LU0889565916.HKD","BK4585","PJP","LU0122379950.USD","BK4588","BK4533","PBE","BK4139","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665387373","title":"BMO下調安進及BioNTech評級至「與大市同步」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665387373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665387373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:59","pubTimestamp":1788872377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BFTCPJ56.SGD","LU0058720904.USD","LU1023059063.AUD","LU2089984988.USD","BK4599","BBH","LU2112291526.USD","LU2242646821.SGD","LU1061106388.HKD","IE0002141913.USD","BK4566","LU2468319806.SGD","LU0889565916.HKD","BK4585","IE00B2B36J28.USD","BK4533","IE00BJJMRZ35.SGD","TBXU","SG9999001440.SGD","LU1983299246.USD","BK4581","IBBQ","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4139","IBB","LU0289739699.SGD","LU0122379950.USD","BK4534","LU2242652126.USD","LU0109394709.USD","PJP","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","BIB","LU1057294990.SGD","LU1571399168.USD","LU0868494617.USD","PBE","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378020","title":"苑東生物：公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378020","media":"证券日报 ","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:16","pubTimestamp":1788869760,"startTime":"0","endTime":"0","summary":"9月8日，苑东生物发布公告称，公司将于9月16日参加科创板2026年半年度创新药行业集体业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","LNGR","688513","159992","BK1574","BK0239","BK1161","MEDX","KSTR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320617","title":"禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320617?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788869000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 发布公告，公司近日就AP308的新药临床试验申请获美国食品药品监督管理局批准，将启动一项AP308用于治疗IgA肾病的首次人体临床试验。就公司所知，AP308为首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。该平台具有优异的稳定性及成药性，并可在保留蛋白酶对IgA1高效切割活性的同时，显著延长药物体内半衰期、降低肾脏清除并减弱免疫原性，为长效、低频次给药奠定基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BMED","BK1574","MDTX","09939","IBBJ","159151","IBBQ","159938","PSYK","BK1515","BK1161","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103332998","title":"美股盤前｜英特爾、甲骨文升逾4%；諾華重挫12%，IONIS下跌10%；阿斯麥新一代EUV光刻機獲台積電和三星使用承諾","url":"https://stock-news.laohu8.com/highlight/detail?id=1103332998","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103332998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868860,"startTime":"0","endTime":"0","summary":"9月8日美元指数上升0.0364%，报98.96。03 要闻1. 三大芯片厂全面采购ASML最先进High NA EUV光刻机以扩产高端制程。ASML确认三星、台积电与英特尔已承诺在2028–2030年起量产使用High NA设备，并与ASML签订光罩尺寸升级合作协议，助力降低AI芯片制造成本。","market":"hk","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823039010.USD","IE000BZT7R73.USD","PXI","IE00BKVL7J92.USD","BK4591","LU1935043023.USD","LU2111349929.HKD","LU1894683348.USD","LU2250418816.HKD","LU1718418525.SGD","CHPX","LU2087625088.SGD","IE00BLSP4452.SGD","BK4612","LU1316542783.SGD","LU1074936037.SGD","IGE","NVS","LU2108987350.USD","UDOW","LU1066053197.SGD","LU2471134952.CNY","LU0661504455.SGD","CHPS","IE00BMPRXR70.SGD","AVSE","LU1712237335.SGD","LU1815336760.USD","LU1989772923.USD","LU2764263039.SGD","LU0081259029.USD","LU0072461881.USD","LU1988902786.USD","BK4533","LU0124676726.USD","BK4588","LU2028103732.USD","AVXC","LU2347655156.SGD","CGIC","LU0300736062.USD","SPY","LU0238689110.USD","IE0002141913.USD","LU0154236417.USD","LU0321505439.SGD","LU1048588211.SGD","LU1974910355.USD",".DJI","IE00B4R5TH58.HKD","LU1201861249.SGD","IE00BFXG1179.USD","LU0130103400.USD","LU0158827781.USD","LU2242649171.HKD","LU0162691827.USD","LU0234572021.USD","RSPG","LU1267930490.SGD","SG9999014559.SGD","IE00B19Z3581.USD","LU1153585028.USD","LU0359201885.HKD","LU1935042215.USD","AIQ","IE00BKPKM429.USD","CGDG","BK4585","LU0965509101.SGD","BK4548","LU0417517546.SGD","LU1282649067.USD","LU2360108059.USD","LU0345769631.USD","LU2247934214.USD","LU2720916845.USD","LU0787776722.HKD","DXD","IE000MB6IJN5.SGD","LU1267930227.SGD","BK4157","LU0572939691.SGD","LU2211814178.USD","LU2087621335.USD","BK4170","LU1046421795.USD","LU2133065610.SGD","IBB","FTXN","LU0274383776.USD","LU0528227936.USD","LU0143551892.USD","BK4138","LU0949170772.SGD","LU2506952170.USD","LU0314106906.USD","LU2324357040.USD","AIS","LU2272731865.HKD","LU2360032135.SGD","LU0889565833.HKD","BK4566","IE000SO60NU8.SGD","LU0965508806.USD","LU1778281490.HKD","IE00B19Z4B17.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0345774631.USD","IE000F7OJYX1.SGD","IYE","SGXZ99366536.SGD","LU0084288322.USD","SG9999014542.SGD","IE0009355771.USD","LU1267930813.SGD","BIB","LU0203347892.USD","LU0256863811.USD","LU2999663052.SGD","LU0109394709.USD","LU2362541273.HKD","LU0143863198.USD","SG9999000418.SGD","SGXZ57979304.SGD","LU2750360641.GBP","LU0011850046.USD","SG9999011175.SGD","SG9999015358.SGD","FCG","IE00B7SZLL34.SGD","LU0094547139.USD","LU0823421333.USD","LU1992135399.USD","LU0158827948.USD","QTUP","IE0000B7K699.USD","LU1282649810.SGD","LU0738911758.USD","BGIA","LU0316494557.USD","SG9999002224.SGD","LU0267386448.USD","LU0882574055.USD","LU1868838027.USD","IE00B775SV38.USD","LU0266512473.USD","LU1804176565.USD","BK4599","LU0320765489.SGD","ORCZ","BBH","LU2357627491.SGD","BK4515","LU2272731782.SGD","IE00BQXX3F31.USD","LU1435385759.SGD","LU1989764748.USD","BK4543","LU0572940350.SGD","LU0868494708.USD","IE00BFXG0V08.USD","ORCS","EMM","TEK","BK7104","TEXU","LU1674673428.USD","DOG","LU2054465674.USD","IE00BN8TJ469.HKD","LU0097036916.USD","LU1720051108.HKD","LU0170899867.USD","DRLL","INYY","LU1037948897.HKD","LU2272731600.USD","ORCX","LU2211815571.USD","LU1868837565.USD","LU0109392836.USD","LU0345774391.USD","LU0868486357.SGD","LU0300736492.USD","LU1732799900.SGD","LU0878004406.USD","LU2112291526.USD","XNTK","03145","LU0251131958.USD","CNEQ","LU1093756168.USD","LU2360107168.USD","LU0957791311.USD","LU0689626769.HKD","LU0642271901.SGD","CTEX","LU0320765646.SGD","LU0211327993.USD","SG9999002521.SGD","LU2326559502.SGD","BK4516","GNMX","LU0912757837.SGD","LU1366192091.USD","LU2505996681.GBP","SG9999014575.USD","LU0310799852.SGD","HK0000304805.HKD","LU0823038988.USD","IE00B2B36J28.USD","LU2264538146.SGD","LU1023059063.AUD","LU1003077747.HKD","LU0965509283.SGD","LU0211331839.USD","QQQA","LU1791710582.SGD","TRUN","LU1066051498.USD","THNR","BK4512","WQTM","BLOX","LU0985489474.SGD","LU0068578508.USD","VDE","LU1642822529.SGD","LU0612318385.USD","LU0719512351.SGD","LU0029874061.USD","LINT","LU1093756325.SGD","LU0266512127.USD","LU2491050071.SGD","LU0795875169.SGD","LU1934455194.USD","DIG","LU0466842654.USD","LU0859254822.USD","LU2468319806.SGD","LU2473716301.USD","ORCL","LU0496365809.HKD","TNGY","BK4007","LU0234570918.USD","LU2023251221.USD","LU1064131342.USD","LU2290526834.HKD","WEEI","LU2041044095.USD","LU0889566641.SGD","LU0553294199.USD","IE0004086264.USD","LU2360106780.USD","IE0004445239.USD","BK4527","IE00B5TLWC47.USD","LU0433182093.SGD","FENI","LU2543165471.USD","TINS","LU0444971666.USD","LU1366333091.USD","LU1989771016.USD","WUGI","LU1815333072.USD","LU0541501648.USD","LU0868494617.USD","LU0048584097.USD","LU1803068979.SGD","BK4526","CGNG","LU0889565916.HKD","LU0149725797.USD","LU1989764664.SGD","LU2487616109.SGD","LU0187121727.USD","EPAI","IE0034235303.USD","GNOM","LU0122376428.USD","LU1934455277.USD","LU2089283258.USD","IE00BGHQF524.EUR","LU0130517989.USD","LU2458330169.SGD","GSID","LU0878005551.USD","SG9999001424.SGD","DBEU","LU0823417737.USD","LU1582986359.USD","ORCU","LU0353189680.USD","ADVE","LU0788109394.HKD","LU1823568750.SGD","LU1791710400.SGD","SG9999013999.USD","SG9999004220.SGD","BK4570","LU0476273544.USD","BK4532","LU0368265418.SGD","IE000WAW04H5.SGD","IE00BWXC8680.SGD","IE00BLSP4239.USD","LU2265009873.SGD","LU0431992006.USD","BK4592","LU0980610538.SGD","LU2237957811.SGD","LU0683600562.USD","LU2471134879.HKD","LU0114720955.EUR","LU2746668974.SGD","BK4535","CQTM","LU0348723411.USD","LU1623119135.USD","LUMA","LU0130102774.USD","LU1211504680.USD","LU2089985449.USD","IE00BQXX3C00.GBP","LU1992135472.HKD","LU1935042488.USD","LU0289960550.SGD","LU0823434740.USD","DDM","IE00BQXX3D17.EUR","LU0056508442.USD","LU0058720904.USD","LU2746668461.USD","LU0098860793.USD","LU0061474960.USD","CGGO","LU2089984988.USD","LU2242652126.USD","IE00B1XK9C88.USD","LU0359201612.USD","LU2089284900.SGD","BK4538","SG9999003800.SGD","TDIV","LU0211326755.USD","LU1037948541.HKD","LU2092937221.SGD","LU0345780950.USD","LU0654597011.USD","TBXU","LU1934455863.HKD","LU0882747503.HKD","LU0792757196.USD","LU0823416689.USD","SPWO","INTW","LU0976567544.SGD","IE00BMPRXN33.USD","BK4504","LU1323610961.USD","FOTO","DRIV","LU0251132253.USD","IE0004091025.USD","LU2271345857.HKD","LU1506573853.SGD","LU1057294990.SGD","BK4602","IE00BZ1G4Q59.USD","IE00BMPRXQ63.HKD","LU1430594728.SGD","LU0345769128.USD","LU2462591277.SGD","FFGX","OGIG","LU0211326839.USD","LU0942090050.USD","LU0345781412.USD","LU0950375773.USD","BK4148","KNOW","SGXZ51526630.SGD","LU1150488135.SGD","SG9999014567.USD","LU1582987324.SGD","DBEF","ESIM","LU2125154778.USD","LU0353189763.USD","LU2462611646.USD","OZEM","LU1430597077.USD","LU2362540622.SGD","LU0070302665.USD","IE00BBT3K403.USD","LU2298321311.HKD","LU2244417387.USD","LU0742534661.SGD","HBMX","IE00B66KJ199.SGD","LU1035773651.USD","LU2506951958.HKD","LU1883866441.USD","EFA","LU0143863784.USD","LU2505996509.AUD","LU2506951792.HKD","SPTE","IE00B19Z3B42.SGD","IE00BD6J9T35.USD","SG9999001176.SGD","BK4097","GXPE","LU1917777945.USD","LU1861220033.SGD","SG9999001176.USD","LU0878866978.SGD","LU0082616367.USD","SMH","BK4139","LU0052756011.USD","LU0128526141.USD","LU0359202008.SGD","IE0009356076.USD","LU1734074674.USD","BK4578","LU0157215616.USD","LU2294711713.HKD","CRAK","LU2458330243.SGD","LU2506952097.USD","LU2129689605.HKD","BK4554","INTC","LU0266013472.USD","LU1861215975.USD","LU1989772840.SGD","UMMA","03165","ERX","PBE","LEGR","SPRX","BK4608","LU2860962120.EUR","LU0456854461.SGD","BK4575","IE00BYQQ9H92.USD","LU0957808578.USD","PXE","LU0128525689.USD","IXC","IEO","LU0648001328.SGD","IGV","LU0072462343.USD","LU2491049909.HKD","BK4213","LU1894683264.USD","LU0965509010.AUD","LU1983299246.USD","IEFA","LU1508157978.USD","LU1852331112.SGD","LU1023057109.AUD","ILOW","IFLR","LU1201861165.SGD","SDOW","BK4023","LU0077335932.USD","LU2237957902.USD","LU2237443549.SGD","LU2602419157.SGD","IE00BZ199S13.USD","LU0310800965.SGD","LU2357305700.SGD","LU0823414478.USD","IE00B2Q91V27.USD","IE0002270589.USD","LU2102340556.USD","LU2471134523.USD","ASMH","BK4581","LU2592432038.USD","PJP","LU0545039389.USD","LU2129689514.USD","IE000M9KFDE8.USD","IE00B3CCJ963.GBP","LU1429558221.USD","LU2125154935.USD","LU2663582299.SGD","LU0861579265.USD","PPH","CORO","IE00B7SZL793.SGD","PQNT","ORAC","LU0541502299.USD","LU1691799644.USD","FDTX","LU0795875086.SGD","BK4147","LU1732800096.USD","LU1839511570.USD","CNAV","LU0138981039.USD","LU0345770993.USD","LU1674673691.USD","LU2237443622.USD","BK4503","LU2362541513.USD","SG9999002232.USD","LU1489326972.SGD","IE00B3S45H60.SGD","LU2242646821.SGD","MEDX","OILT","LU0630314457.HKD","SG9999001440.SGD","LU0070217475.USD","IE00BSNM7G36.USD","BK7095","LU2148611432.USD","LU0211328371.USD","LU0264606111.USD","LU2430703095.HKD","LU0198837287.USD","LU2896262040.SGD","LU1582986433.USD","BK4201","LU0203345920.USD","LU2129689431.USD","EMC","DIA","BK4605","LU2764262908.HKD","LU2931357623.SGD","BK4505","LU2357125470.USD","INT","LU0823414551.USD","XLE","LU0612318971.USD","LU2249611893.SGD","LU0278409577.USD","IE00B5949003.HKD","LU0323591593.USD","LU1935043536.SGD","BK4141","LU1061106388.HKD","BK4579","IE00BKDWB100.SGD","HYDR","LU0208291251.USD","SGXZ81514606.USD","LU0251142724.SGD","LU2750360997.AUD","LU1868837722.USD","LU0488056044.USD","IE00BHPRN162.USD","LU0823421416.USD","LU1150488218.USD","LU0384037296.USD","LU2430703178.SGD","BK4082","LU2471134796.USD","IE00B3M56506.USD","LU1571399168.USD","BK4559","BK4550","IE00BFTCPJ56.SGD","LU0345770308.USD","LU0048573561.USD","LU0210528500.USD","LU2491050154.USD","SOXX","LU0122379950.USD","LU0154245673.USD","BK4528","HK0000304797.USD","LU0648000940.SGD","LU0823417653.USD","TTEQ","CHAT","AVEM","LU1235294995.USD","IBBQ","LU0477156953.USD","LU0321505868.SGD","LU2322448791.USD","LU0320765992.SGD","LU0154245756.USD","LU1585245621.USD","FTXL","LU1935042991.SGD","LU1929549753.HKD","LU2430703251.USD","BK4121","LU2506951875.HKD","LU0225283273.USD","LU2764263203.CNY","LU2236285917.USD","LU0432979614.USD","BAI","LU0444973449.USD","LU0256331488.USD","LU1548497426.USD","LU1582987597.SGD","SG9999015341.SGD","LU1720051017.SGD","LU2063271972.USD","LU2237443978.SGD","LU2237443382.USD","BK4534","FENY","LU2322448957.HKD","LU0175139822.USD","IE0031619046.USD","LU0823434583.USD","LU2023250504.SGD","ASIA","LU2498475776.HKD","LU2106854487.HKD","LU2954938101.SGD","LU1069347547.HKD","LU0210536198.USD","EGGY","IE00B1BXHZ80.USD","MEMX","CWI","LU0053666078.USD","BK4529","LU1162221912.USD","LU1291159041.SGD","BK5113","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320908","title":"AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320908","media":"独角兽智库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320908?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:44","pubTimestamp":1788867840,"startTime":"0","endTime":"0","summary":"AI 制药行业已经走过早期概念炒作阶段，产业验证层级持续向上，从算法叙事正式转向管线价值兑现，行业商业化拐点正在加速到来。随着 AI 制药行业持续发展，生物测序数据需求持续扩张，设备与试剂业务打开增量空间，站在产业链上游充分受益行业整体景气上行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-08/doc-inircmes6042281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","ARTY","BK1574","AIPO","CHAT","LNGR","MEDX","BK1191","AGIX","QTOC","IBBQ","159992","VTHR","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324003","title":"PHARVARIS的3期臨床試驗達到全部主要及次要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324003?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:53","pubTimestamp":1788864791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","BMED","IBBQ","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329150","title":"石藥集團：SYH2083滴眼液獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329150?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:51","pubTimestamp":1788861091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","PSYK","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329827","title":"膽固醇藥物臨床試驗受挫，數十億美元研發競賽蒙上陰影","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329827","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:33","pubTimestamp":1788859980,"startTime":"0","endTime":"0","summary":"受该消息影响，诺华周一股价下跌 3%。诺华表示完整试验结果将在后续医学学术大会上公布。诺华强调，本次 8000 多名受试者均已接受最优标准治疗。诺华失利，安进与礼来压力陡增此前分析师测算，如果 pelacarsen 临床试验成功，其销售峰值有望达到每年 4050 亿美元。但该临床试验的冲击不止波及诺华一家。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4625928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PSYK","BMED","IBBJ","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665215326","title":"諾華試驗受挫且BMO下調評級，安進股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2665215326","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665215326?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:27","pubTimestamp":1788859661,"startTime":"0","endTime":"0","summary":"BUZZ-诺华试验受挫且BMO下调评级，安进股价下跌9月8日-** 安进公司（AMGN.O）股价盘前下跌4.8%，至416美元** 诺华公司（NOVN.S）的降胆固醇药物在一项备受关注的研究中未能达标，这引发了市场对安进公司（Amgen）实验性降胆固醇药物olpasiran的担忧 (link)** 摩根大通分析师表示，诺华的pelacarsen研究结果降低了市场对安进olpasiran的预期，而该","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4500MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0002141913.USD","LU0889565916.HKD","TBXU","LU1061106388.HKD","PBE","IE00B4R5TH58.HKD","IBB","IE00B2B36J28.USD","LU1023059063.AUD","AMGN","LU2242646821.SGD","SG9999001440.SGD","BK4581","LU0058720904.USD","PJP","LU1057294990.SGD","LU1571399168.USD","BK4585","BK4566","LU2089984988.USD","BK4534","LU2242652126.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4139","IE00BJJMRZ35.SGD","BK4599","LU0868494617.USD","LU1983299246.USD","LU0122379950.USD","LU2112291526.USD","BBH","BK4533","IE0009355771.USD","BK4588","BIB","IBBQ","LU0289739699.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132698","title":"復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132698","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132698?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:13","pubTimestamp":1788858794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS5626片用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。复星医药产业拟于条件具备后于中国境内开展该药品的相关临床研究。截至2026年8月，公司现阶段针对FXS5626的累计研发投入约为1.08亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0188","BK0028","BK0196","BMED","BK0060","BK0175","BK0239","IBBQ","BK0187","BK1515","PSYK","MDTX","600196","02196","IBBJ","BK1593","BK0096","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176595225","title":"盤前異動：安進、耐克、Bloom Energy 等個股受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=1176595225","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176595225?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:10","pubTimestamp":1788858632,"startTime":"0","endTime":"0","summary":"安进：这家生物科技巨头、道琼斯指数的重要权重股，其盘前股价重挫逾5%。此前，瑞士制药商诺华宣称，其一款实验性药物在晚期临床试验中未能有效降低心血管风险。安进与礼来目前正在各自研发竞品疗法以应对挑战。消息传出后，诺华在欧股市场大跌10%，礼来股价亦小幅走低。Bloom Energy：这家燃料电池制造商可谓利好连连。受此提振，其盘前股价上扬4%。游戏驿站定于今日美股收盘后发布财报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WATS","BK4139","MEDX","IE00B4R5TH58.HKD","OWNB","LU2468319806.SGD","LU0823414551.USD","LU0052756011.USD","LU0792757196.USD","VCLN","LU1861558580.USD","LU1303367103.USD","BK4146","COIW","HOOC","COIN","MSTK","MSTX","BK4182","CONL","HOOI","HOOX","LU0029864427.USD","AMGN","BK4554","SMST","COIG","LMI3.UK","GMEU","LU1861220207.SGD","IE0009355771.USD","BK4535","IE00BJJMRZ35.SGD","BK4539","MST","IMST","LU2264538146.SGD","BK4532","MSTW","BK4577","BK4561","LU0211331839.USD","BK4112","PPH","BK4581","BEX","LU1267930573.SGD","BK4596","BK4127","LU0476273544.USD","IE00BYQQ9H92.USD","BK4541","BITQ","TBXU","BK4516","IE0009354923.USD","BK4547","BK4533","MSTZ","CONX","MSTY.UK","BK4076","LU1571399168.USD","BPAY","LU0868494617.USD","LU1057294990.SGD","07711","GMEY","IAI","BK4023","COIO","ICLN","LU0058720904.USD","LU1267930813.SGD","IGME","BK4566","BEC","LU1064131342.USD","ZAP","LU0889565916.HKD","IBB","LU1642822529.SGD","BIB","EGGY","COIA","SIMS","WNTR","BE","BK4588","BLCK","CRPT","ROBN","HOII","LU0444971666.USD","FDIG","LU2294711713.HKD","MSOO","IE00BJT1NW94.SGD","MSTU","UPGR","BK4595","LU0444973449.USD","BK4558","BK4007","LU0070302665.USD","LU2242652126.USD","LU0289739699.SGD","LU1815336760.USD","HOOD","LU0320765992.SGD","STYL","09711","3SMI.UK","LU0128525929.USD","LU0889566641.SGD","LU1861217088.USD","09399","LU1267930227.SGD","04332","LU2357125470.USD","PJP","LU2543165471.USD","IE00B2B36J28.USD","LU2098885051.SGD","LU2360107671.USD","COIX","07311","BEZ","BK4600","07399","IE0002141913.USD","FINX","IE00BFTCPJ56.SGD","BK4578","APED","FIAT","HOOG","LU2242646821.SGD","MSTC","FRNW","GMEC","LU0823411888.USD","LU0310800379.SGD","CTEC","CONI","LU0957808578.USD","LU1061106388.HKD","SG9999001440.SGD","MTYY","BBH","LU0708994859.HKD","LU0310800965.SGD","BK4585","MSII","MSTR","COII","LU0128525689.USD","GME","LU0208291251.USD","MSTY","BK4534","NVS","09799","HOOW","NKE","IE00BFXG0V08.USD","CONY","IBLC","3LMI.UK","PBE","SMI3.UK","DAPP","MSDD","MSST","LU2506951792.HKD","MSTP","IBAT","LU2089984988.USD","BK4551","LU2112291526.USD","BK4599","COYY","SMOG","HODU","LU1988902786.USD","CNRG","LU1861559042.SGD","VTWG","LU0320765489.SGD","LU0122379950.USD","09311","LU2249611893.SGD","IBBQ","BEG","HOYY","LU0823414478.USD","LU1023059063.AUD","ICOI","HOOZ","LU0786609619.USD","LU1983299246.USD","BKCH","07799","HOOY","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326953","title":"美股異動｜安進盤前跌5.4%，諾華同靶點藥物III期臨床失敗，Lp(a)賽道遭重創","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326953","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326953?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:07","pubTimestamp":1788858422,"startTime":"0","endTime":"0","summary":"消息面上，诺华于9月4日公布，其与Ionis联合开发的降脂药物Pelacarsen，在名为LpHORIZON的III期临床试验中未能达到主要终点。诺华的Pelacarsen是全球首个针对Lp靶点进行心血管结局验证的III期药物。因此，市场担忧情绪蔓延到了同样在开发Lp药物的安进身上。多家分析机构认为，诺华的失败削弱了但并未完全推翻Lp这一靶点的可行性。安进后续公布的Olpasiran完整试验数据，将成为判断该靶点未来走向的关键。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1983299246.USD","BK4007","BK4566","LU0122379950.USD","LU0320765992.SGD","BK4581","BK4533","LU2468319806.SGD","PPH","LU0211331839.USD","IE00BJT1NW94.SGD","BK4578","LU0320765489.SGD","BK4585","IBBQ","BK4534","IE00BFTCPJ56.SGD","LU2242652126.USD","LU0070302665.USD","AMGN","IBB","LU0868494617.USD","BK4588","LU1057294990.SGD","LU0889565916.HKD","IE00B2B36J28.USD","LU0109394709.USD","BK4532","BBH","LU0289739699.SGD","IE0009355771.USD","LU1061106388.HKD","LU0058720904.USD","PBE","BK4599","BIB","NVS","LU2089984988.USD","MEDX","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1571399168.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","PJP","LU2112291526.USD","LU1023059063.AUD","BK4139","TBXU","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":5,"totalSize":201,"code":"91000000","status":"200"}]}}